Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor β receptor II improves colitis but exacerbates autoimmune cholangitis
Open Access
- 15 March 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 52 (1), 215-222
- https://doi.org/10.1002/hep.23664
Abstract
The role of interleukin-6 (IL-6) in autoimmunity attracts attention because of the clinical usage of monoclonal antibodies to IL-6 receptor (IL-6R), designed to block IL-6 pathways. In autoimmune liver disease, activation of the hepatocyte IL-6/STAT3 (signal transducer and activator of transcription 3) pathway is associated with modulating pathology in acute liver failure, in liver regeneration, and in the murine model of concanavalin A–induced liver inflammation. We have reported that mice expressing a dominant negative form of transforming growth factor β receptor II (dnTGFβRII) under control of the CD4 promoter develop both colitis and autoimmune cholangitis with elevated serum levels of IL-6. Based on this observation, we generated IL-6–deficient mice on a dnTGF-βRII background (dnTGFβRII IL-6−/−) and examined for the presence of antimitochondrial antibodies, levels of cytokines, histopathology, and immunohistochemistry of liver and colon tissues. As expected, based on reports of the use of anti–IL-6R in inflammatory bowel disease, dnTGFβRII IL-6−/− mice manifest a dramatic improvement in their inflammatory bowel disease, including reduced diarrhea and significant reduction in intestinal lymphocytic infiltrates. Importantly, however, autoimmune cholangitis in dnTGFβRII IL-6−/− mice was significantly exacerbated, including elevated inflammatory cytokines, increased numbers of activated T cells, and worsening hepatic pathology. Conclusion: The data from these observations emphasize that there are distinct mechanisms involved in inducing pathology in inflammatory bowel disease compared to autoimmune cholangitis. These data also suggest that patients with inflammatory bowel disease may not be the best candidates for treatment with anti–IL-6R if they have accompanying autoimmune liver disease and emphasize caution for therapeutic use of anti–IL-6R antibody. HEPATOLOGY 2010Keywords
This publication has 60 references indexed in Scilit:
- Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor β receptor type II miceHepatology, 2009
- Primary biliary cirrhosis is associated with altered hepatic microRNA expressionJournal of Autoimmunity, 2009
- Cholangiocyte proliferation and liver fibrosisExpert Reviews in Molecular Medicine, 2009
- Apotopes and the biliary specificity of primary biliary cirrhosisHepatology, 2009
- Hepatic IL-17 responses in human and murine primary biliary cirrhosisJournal of Autoimmunity, 2008
- The effects of IL-6 on CD4 T cell responsesClinical Immunology, 2008
- Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitisHepatology, 2008
- Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Rα−/− miceHepatology, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Adoptive transfer of CD8+ T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in miceHepatology, 2008